European consensus table on the use of botulinum toxin type A in adult spasticity

J Rehabil Med. 2009 Jan;41(1):13-25. doi: 10.2340/16501977-0303.


A group of clinicians from across Europe experienced in the use of botulinum toxin type A for the treatment of spasticity following acquired brain injury gathered to develop a consensus statement on best practice in managing adults with spasticity. This consensus table summarizes the current published data, which was collated following extensive literature searches, their assessment for level of evidence and discussion among the whole group. Published information is supplemented by expert opinion based on clinical experience from 16 European countries, involving 28 clinicians, who treat an average of approximately 200 patients annually, representing many thousand spasticity treatments with botulinum toxin per year.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Botulinum Toxins, Type A / administration & dosage*
  • Brain Injury, Chronic / complications
  • Consensus
  • Evidence-Based Medicine
  • Follow-Up Studies
  • Humans
  • Hypoxia, Brain / complications
  • Injections, Intramuscular
  • Motor Activity / drug effects
  • Motor Neuron Disease / drug therapy*
  • Motor Neuron Disease / etiology
  • Muscle Spasticity / drug therapy*
  • Muscle Spasticity / etiology
  • Neuromuscular Agents / administration & dosage*
  • Stroke / complications


  • Neuromuscular Agents
  • Botulinum Toxins, Type A